Please assess the completion status of the following clinical trial:

Trial Title: The Effects of INP on Peripheral Circulation in Dialysis Patients and Patients With PAD and Leg Ulcers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able and willing to provide informed consent~* Age: 18-96 years~* Affected foot/shoe size \<46 (approximate foot length\< 29,5 cm)~* Receiving hemodialysis ≥3 times per week for 1 hour per treatment OR~* Peripheral arterial disease and leg ulcer~Exclusion criteria:~* Incapable to consent voluntarily, i.e. patients who are not able to consent due to their mental status, or who are not willing or able to perform the negative pressure therapy in a sitting position~* Not adhering to the INP therapy program~* Patients with an expected life-span less than 3 months~* Patients in whom the remaining limb is non-functional, for example due to previous stroke~* Patients in which a deep venous thrombosis or pulmonary embolism is suspected~* Limbs with uncontrolled infection~* Previous lumbar sympathectomy~* Bilateral amputation of lower extremity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 96 Years
- Healthy Volunteers: f

Study Arms:
- single-case design (Type: EXPERIMENTAL): The study design will be a non-randomized clinical trial with single-subject baseline design (also called single-case baseline design) where each patients act as their own controls:~Observations (A) will be taken before and after a 8-week intervention period. We plan to introduce a 4-week INP-treatment period ('FlowOx™) (B) using the same outcome variables that were used as baseline measures. If the patient demonstrates improvements in outcome variables after the first treatment period (B1), the patient will be asked to continue INP therapy for another 4-week period, before a final assessment after a total of 8-week intervention period (B2) (A-B-B design).

Based on this trial design, predict the completion outcome and termination type (if applicable).